2 weeks Esperion Therapeutics (ESPR) Reports Q4 Loss, Lags Revenue Estimates Zacks
Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 28.57% and 1.28%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
X